LBA
GSK icon

Letko, Brosseau & Associates’s GSK GSK Stock Holding History

Letko, Brosseau & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.2M Sell
1,624,668
-19,945
-1% -$1.05M 1.26% 30
2026
Q1 		$90.8M Sell
1,644,613
-30,250
-2% -$1.64M 1.46% 27
2025
Q4 		$82.1M Sell
1,674,863
-1,105
-0.1% -$51.5K 1.34% 27
2025
Q3 		$72.3M Buy
1,675,968
+14,700
+0.9% +$574K 1.24% 31
2025
Q2 		$63.8M Buy
1,661,268
+41,850
+3% +$1.6M 1.22% 33
2025
Q1 		$62.7M Sell
1,619,418
-3,785
-0.2% -$139K 1.33% 33
2024
Q4 		$54.9M Buy
1,623,203
+398,433
+33% +$14.3M 1.06% 40
2024
Q3 		$50.1M Buy
1,224,770
+40,675
+3% +$1.66M 0.91% 44
2024
Q2 		$45.6M Buy
1,184,095
+5,900
+0.5% +$248K 0.86% 47
2024
Q1 		$50.5M Sell
1,178,195
-1,740
-0.1% -$71.8K 0.88% 45
2023
Q4 		$43.7M Sell
1,179,935
-18,033
-2% -$647K 0.8% 48
2023
Q3 		$43.4M Buy
1,197,968
+10,515
+0.9% +$373K 0.85% 45
2023
Q2 		$42.3M Buy
1,187,453
+3,185
+0.3% +$114K 0.79% 47
2023
Q1 		$42.1M Buy
1,184,268
+7,875
+0.7% +$276K 0.79% 46
2022
Q4 		$41.3M Buy
1,176,393
+632,160
+116% +$21.1M 0.74% 49
2022
Q3 		$16M Buy
+544,233
New +$20.6M 0.32% 69
2022
Q2 		– Sell
-535,478
Closed -$29.2M – 102
2022
Q1 		$29.2M Sell
535,478
-10,904
-2% -$592K 0.43% 68
2021
Q4 		$30.1M Buy
546,382
+1,492
+0.3% +$77.6K 0.43% 66
2021
Q3 		$26M Sell
544,890
-3,200
-0.6% -$161K 0.38% 67
2021
Q2 		$27.3M Buy
548,090
+30,596
+6% +$1.47M 0.36% 65
2021
Q1 		$23.1M Buy
517,494
+2,960
+0.6% +$134K 0.32% 69
2020
Q4 		$23.7M Sell
514,534
-33,048
-6% -$1.52M 0.32% 66
2020
Q3 		$25.8M Sell
547,582
-57,384
-9% -$2.88M 0.4% 61
2020
Q2 		$30.8M Sell
604,966
-16,040
-3% -$823K 0.46% 60
2020
Q1 		$29.4M Sell
621,006
-2,020
-0.3% -$108K 0.5% 56
2019
Q4 		$36.6M Sell
623,026
-29,552
-5% -$1.64M 0.36% 63
2019
Q3 		$34.8M Sell
652,578
-33,600
-5% -$1.73M 0.36% 62
2019
Q2 		$34.3M Sell
686,178
-41,376
-6% -$2.08M 0.35% 64
2019
Q1 		$38M Sell
727,554
-55,884
-7% -$2.79M 0.38% 63
2018
Q4 		$37.4M Sell
783,438
-19,668
-2% -$969K 0.42% 60
2018
Q3 		$40.3M Sell
803,106
-21,980
-3% -$1.12M 0.37% 63
2018
Q2 		$41.6M Sell
825,086
-11,284
-1% -$568K 0.38% 64
2018
Q1 		$40.8M Buy
836,370
+14,220
+2% +$662K 0.38% 59
2017
Q4 		$36.5M Buy
822,150
+24,000
+3% +$1.11M 0.32% 61
2017
Q3 		$40.5M Buy
798,150
+3,700
+0.5% +$188K 0.37% 59
2017
Q2 		$42.8M Sell
794,450
-11,660
-1% -$622K 0.42% 58
2017
Q1 		$42.5M Sell
806,110
-9,248
-1% -$469K 0.4% 58
2016
Q4 		$39.2M Sell
815,358
-36,836
-4% -$1.82M 0.36% 59
2016
Q3 		$45.9M Sell
852,194
-19,560
-2% -$1.07M 0.43% 57
2016
Q2 		$47.2M Sell
871,754
-11,640
-1% -$613K 0.45% 56
2016
Q1 		$44.8M Sell
883,394
-34,160
-4% -$1.7M 0.44% 59
2015
Q4 		$46.3M Sell
917,554
-37,940
-4% -$1.93M 0.48% 58
2015
Q3 		$45.9M Sell
955,494
-12,388
-1% -$645K 0.47% 55
2015
Q2 		$50.4M Buy
967,882
+84,352
+10% +$4.75M 0.46% 56
2015
Q1 		$51M Buy
883,530
+7,960
+0.9% +$456K 0.48% 55
2014
Q4 		$46.8M Buy
875,570
+859,850
+5,470% +$48.1M 0.41% 58
2014
Q3 		$903K Hold
15,720
– – 0.01% 90
2014
Q2 		$1.05M Sell
15,720
-520
-3% -$35.2K 0.01% 89
2014
Q1 		$1.08M Hold
16,240
– – 0.01% 89
2013
Q4 		$1.08M Sell
16,240
-1,832
-10% -$119K 0.01% 91
2013
Q3 		$1.13M Buy
18,072
+112
+0.6% +$7.21K 0.01% 86
2013
Q2 		$1.12M Buy
+17,960
New +$1.14M 0.01% 86

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Letko, Brosseau & Associates's GSK Position: Q2 2026 in Review

Letko, Brosseau & Associates reduced its GSK (GSK) stake by 1.2% in Q2 2026, selling an estimated $1.05M and leaving 1,624,668 shares worth $85.2M. The position accounts for 1.26% of the portfolio, ranked #30.

Letko, Brosseau & Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $90.8M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Letko, Brosseau & Associates held 1,624,668 shares of GSK worth $85.2M as of Q2 2026.
  • Letko, Brosseau & Associates sold 19,945 GSK shares in Q2 2026, an estimated $1.05M.
  • GSK made up 1.26% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #30 holding.
  • Letko, Brosseau & Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • Letko, Brosseau & Associates's GSK position peaked at $90.8M in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.